Scinosen (Shenzhen) Gene Industry Development Co., Ltd. has established a set of large-scale production process and quality control technical standards for recombinant adenovirus products based on the creation of the world's first independently developed gene therapy anti-cancer drug, "Recombinant Human p53 Adenovirus Injection" (also known as "Jinyousheng").
Scinosen (Shenzhen) Gene Industry Group's CDMO platform for viral vector gene drugs, based on its own core intellectual property rights, professional talent team, unique process research and development capabilities, and large-scale production capabilities, provides integrated services ...
Recombinant human p53 adenovirus injection (Gendice) is a genetically engineered recombinant human p53 gene adenovirus particle (rAd-p53) with infectious activity. It consists of two parts: replication defective human adenovirus type 5 and normal p53 tumor suppressor gene. The replication defective adenovirus particle serves as a carrier to introduce the p53 gene into tumor cells
Innovation is the inexhaustible driving force for the development of Sinogene, and the success of Sinogene today stems from relentless independent innovation. Sinogene is committed to the development and industrialization of new gene therapy technologies, and has developed two major technology platforms: the "viral vector gene transduction system" and the "non viral vector gene transduction system".
Adhering to the concept of communication and cooperation, continuously improving our own strength, providing customers with higher quality products and services, and making greater contributions to the development of the industry.
The science popularization column is carefully crafted by a professional, passionate, and mission driven team. On the path of pursuing a healthy lifestyle, the health science popularization column is like a bright lighthouse, guiding you in the right direction.
An important bridge for communication between the company and the outside world. By timely and accurate news releases, customers, partners, investors, and all sectors of society can better understand the latest developments, development strategies, and core values of the company.
We would like to use cookies to better understand your usage of this website. This will help improve your experience when visiting this website in the future. Regarding the use of cookies and how to revoke or manage your consent, please refer to our 《Privacy Policy》 。 If you click the confirm button on the right, it will be deemed that you agree to the use of cookies.